<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041171</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-60002</org_study_id>
    <secondary_id>CDR0000069449</secondary_id>
    <nct_id>NCT00041171</nct_id>
  </id_info>
  <brief_title>Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery</brief_title>
  <official_title>Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. St. John's wort may interfere with the effectiveness of
      chemotherapy. It is not yet known if chemotherapy is more effective with or without St.
      John's Wort in treating solid tumors.

      PURPOSE: Randomized phase III trial to compare the effectiveness of docetaxel with or without
      St. John's wort in treating patients who have solid tumors that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the effect of Hypericum perforatum (St. John's Wort) on the pharmacokinetic
           clearance of docetaxel in patients with unresectable solid tumors.

        -  Determine the effect of Hypericum perforatum on the production and plasma concentrations
           of M4-C13-hydroxydocetaxel in these patients.

        -  Determine the effects of this drug on the pharmacodynamics of docetaxel in these
           patients.

        -  Determine the relationship between the effects of this drug on docetaxel metabolic
           clearance and CYP3A4/CYP3A5 genotype in these patients.

        -  Determine the relationship between the effect of this drug on docetaxel metabolic
           clearance and p-glycoprotein genotype in these patients.

        -  Determine the relationship between the effect of this drug on docetaxel clearance and
           pregnane receptor genotype in these patients.

        -  Assess compliance with this drug in these patients.

        -  Assess the steady state concentrations of hyperforin, one of the putative psychoactive
           components of Hypericum perforatum, in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients who have not
      been receiving chronic Hypericum perforatum (St. John's Wort) are assigned to group A, while
      a cohort of 8 patients who have been receiving chronic Hypericum perforatum are assigned to
      group B.

        -  Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral placebo three times daily on days 1-14 and docetaxel IV
           over 1 hour on day 15.

        -  Arm II: Patients receive oral Hypericum perforatum three times daily on days 1-14 and
           docetaxel as in arm I.

        -  Group B (non-randomized group): Patients receive docetaxel as in arm I and continue to
           receive their chronic regimen of Hypericum perforatum except on day 15.

      Treatment in both groups repeats every 21 days for 2 courses in the absence of disease
      progression or unacceptable toxicity.

      Patients are followed for new primaries and survival only.

      PROJECTED ACCRUAL: Approximately 92 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was not activated.
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Adult Solid Tumor</condition>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney and Urinary Cancer</condition>
  <condition>Male Reproductive Cancer</condition>
  <condition>Thorax and Respiratory Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: placebo + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.
Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed for new primaries and survival only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Hypericum perforatum + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.
Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed for new primaries and survival only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Hypericum perforatum + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.
Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed for new primaries and survival only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypericum perforatum</intervention_name>
    <arm_group_label>Arm 2: Hypericum perforatum + docetaxel</arm_group_label>
    <arm_group_label>Arm 3: Hypericum perforatum + docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Arm 1: placebo + docetaxel</arm_group_label>
    <arm_group_label>Arm 2: Hypericum perforatum + docetaxel</arm_group_label>
    <arm_group_label>Arm 3: Hypericum perforatum + docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Arm 1: placebo + docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed unresectable solid tumor, including, but not limited to, the
             following:

          -  Lung cancer

          -  Breast cancer

          -  Head and neck cancer

          -  Bladder cancer

          -  Prostate cancer

          -  Must be suitable for treatment with single-agent docetaxel

          -  Hormone receptor status:

          -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Sex:

          -  Male or female

        Menopausal status:

          -  Not specified

        Performance status:

          -  CTC 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin less than upper limit of normal (ULN)

          -  Alkaline phosphatase less than 2.5 times ULN

        Renal:

          -  Creatinine no greater than 1.5 times ULN

          -  BUN no greater than 1.5 times ULN

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior bone marrow transplantation

          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

          -  No prior docetaxel

          -  No more than 2 prior chemotherapy regimens

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent hormonal agents except steroids for adrenal failure or hormones for
             non-disease-related conditions (e.g., insulin for diabetes)

        Radiotherapy:

          -  At least 3 weeks since prior radiotherapy

          -  No concurrent palliative radiotherapy

        Surgery:

          -  At least 4 weeks since prior major surgery

        Other:

          -  At least 6 months since prior Hypericum perforatum (St. John's Wort)

          -  At least 1 week since prior CYP3A enzyme inducers including:

          -  Phenobarbital

          -  Phenytoin

          -  Carbamazepine

          -  Lamotrigine

          -  Rifampin

          -  Rifabutin

          -  Isoniazid

          -  Sulfinpyrazone

          -  Pioglitazone

          -  Anti-HIV drugs such as efavirenz or nevirapine

          -  At least 1 week since prior CYP3A enzyme inhibitors including:

          -  Erythromycin

          -  Clarithromycin

          -  Azithromycin

          -  Roxithromycin

          -  Ketoconazole

          -  Fluconazole

          -  Itraconazole

          -  Metronidazole

          -  Chloramphenicol

          -  Ritonavir

          -  Saquinavir

          -  Indinavir

          -  Nelfinavir mesylate

          -  Delavirdine

          -  Amiodarone

          -  Cyclosporine

          -  Tacrolimus

          -  Sirolimus

          -  Nefazodone

          -  Fluvoxamine

          -  No concurrent CYP3A enzyme inducers

          -  No concurrent CYP3A enzyme inhibitors

          -  No ethanol (especially red wine), grape fruit juice, or seville orange juice (CYP3A
             enzyme inhibitor) within 3 days before or after receiving docetaxel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel D. Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverting papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverting papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverting papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

